Scleroderma and Vasculitis Clinical Trials

(Fully Enrolled) Active - Contact Uzunma Udeh 212.774.2123
Purpose: To determine the safety and tolerability of a medication called Gleevec in systemic sclerosis. Important secondary outcomes of relevance are improvement in disease activity as defined by skin scores and indices of pulmonary function.

Actively recruiting – contact Nina Paddu, 212.774.7194
Purpose: The overall objective of this study is to establish a Scleroderma registry that will support and promote basic science and clinical research of this complex rheumatic disease The Hospital for Special Surgery. The existence of a registry for this rare disorder will facilitate our understanding of the clinical features, pathobiology, genetics and possible methods of intervention associated with it. This will ultimately lead to a potential treatment for this, to date, untreatable disease.

Active
Purpose: To establish a prospective observational longitudinal cohort study of patients with scleroderma who are at high risk for pulmonary hypertension. This registry will aid in the understanding of disease progression in patients with systemic sclerosis and early pulmonary hypertension.

(Fully Enrolled) Active - Contact: Uzunma Udeh 212.774.2123
Purpose: To learn about how safe and tolerable a medication called Nilotinib (Tasigna) will be for patients diagnosed with systemic sclerosis. Nilotinib is a medication on the market which has been FDA approved for the treatment of a type of leukemia called chronic myelogenous leukemia (CML). It is not FDA approved to treat scleroderma or other autoimmune diseases at this time. It is an oral medication, taken as a daily pill.